NASDAQ:AGEN - Agenus Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $8.00
Forecasted Upside: 52.09 %
Number of Analysts: 3
Breakdown:
0 Sell Ratings
0 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$5.26 As of 06/18/2021 01:00 AM ET

▼ -0.06 (-1.13%)

1 month | 3 months | 12 months

Get New Agenus Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGEN

^$8.00

▲ +52.09% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 52.09% upside from the last price of $5.26.

Buy

The current consensus among 3 polled investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/28/2019

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/27/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/23/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/22/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/21/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/15/2021	B. Riley	Reiterated Rating	Buy	$8.00	High
12/10/2020	B. Riley	Reiterated Rating	Buy	$8.00	Medium
9/23/2020	William Blair	Reiterated Rating	Buy		Low
9/18/2020	Jefferies Financial Group	Boost Price Target	Buy	$5.00 ➝ $8.00	Medium
6/22/2020	B. Riley	Reiterated Rating	Buy	$6.00	Low
6/5/2020	B. Riley	Reiterated Rating	Buy	$6.00	Low
5/29/2020	B. Riley	Reiterated Rating	Buy	$6.00	High
5/22/2020	B. Riley	Reiterated Rating	Buy	$6.00	Low
12/20/2019	B. Riley	Initiated Coverage	Buy	$6.00	High
11/19/2019	B. Riley	Initiated Coverage	Buy	$6.00	Low
4/22/2019	B. Riley	Initiated Coverage	Buy ➝ Buy	$5.00 ➝ $5.00	Medium
8/4/2017	Jefferies Financial Group	Reiterated Rating	Buy	$7.00	High
5/6/2017	HC Wainwright	Set Price Target	Hold	$5.00	Low
4/23/2017	Maxim Group	Reiterated Rating	Buy	$7.00	Medium
3/11/2017	Maxim Group	Set Price Target	Buy	$7.00	Low
3/11/2017	HC Wainwright	Set Price Target	Hold	$5.00	Low
2/16/2017	HC Wainwright	Set Price Target	Hold	$5.00	N/A
12/1/2016	JMP Securities	Reiterated Rating	Buy		N/A
10/28/2016	HC Wainwright	Downgrade	Buy ➝ Neutral	$10.00 ➝ $5.00	N/A
10/27/2016	Maxim Group	Reiterated Rating	Buy	$7.00	N/A
8/23/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
7/31/2016	HC Wainwright	Reiterated Rating	Buy	$10.00	N/A
7/29/2016	Jefferies Financial Group	Boost Price Target	Buy	$6.00 ➝ $7.00	N/A
7/28/2016	Maxim Group	Reiterated Rating	Buy	$7.00	N/A
6/22/2016	Maxim Group	Reiterated Rating	Buy		N/A

(Data available from 6/21/2016 forward)

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Today's Range

Now: $5.26

$5.18

$5.38

50 Day Range

MA: $3.70

$2.56

$5.32

52 Week Range

Now: $5.26

$2.50

$5.95

Volume

6,911,700 shs

Average Volume

4,482,785 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Agenus?

The following sell-side analysts have issued stock ratings on Agenus in the last twelve months: B. Riley, Jefferies Financial Group Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for AGEN.

What is the current price target for Agenus?

2 Wall Street analysts have set twelve-month price targets for Agenus in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 52.1%. Jefferies Financial Group Inc. has the highest price target set, predicting AGEN will reach $8.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $8.00 for Agenus in the next year.
View the latest price targets for AGEN.

What is the current consensus analyst rating for Agenus?

Agenus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGEN will outperform the market and that investors should add to their positions of Agenus.
View the latest ratings for AGEN.

What other companies compete with Agenus?

Other companies that are similar to Agenus include Amgen, Gilead Sciences, Biogen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Agenus' investor relations team?

Agenus' physical mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 674-4400 and its investor relations email address is [email protected] The official website for Agenus is agenusbio.com.